The purpose of this paper was to determine the effects of template amount and uracil-DNA glycosylase (UDG) treatment on mutation identification using DNA from formalin-fixed paraffin-embedded (FFPE) lung carcinoma specimens.
Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase.
Do H, Dobrovic A
Purpose
Conclusion
Sequencing and high resolution melting (HRM) artifacts in FFPE specimens were decreased by UDG treatment of the DNA or by increasing the template amount. UDG treatment did not impact true mutation detection.
Studies (1)
Purpose
The purpose of this study was to determine the effects of template amount and UDG treatment on identification of sequence mutations using DNA from FFPE lung carcinoma specimens. DNA was extracted from 73 FFPE lung carcinoma specimens using the DNeasy kit and was stored for 7-17 years.
Summary of Findings
15 of the 73 specimens were identified to have sequence variants in RAC-alpha serine/threonine-protein kinase (AKT1) by HRM analysis, but none of the variants were the known E17K variant. All of the identified variants were single base substitutions, and 16 of 17 identified mutations in AKT1 were C:G>T:A. When the input was increased from 5 ng to 25 ng, 4 of 5 specimens were found to be wild-type. Adding UDG (0.1-1 units/reaction) also reduced mutation identification and did not affect cycle threshold value. In 3 specimens that had AKT1 mutations identified in 57% (34 of 60), 40% (24 of 60) and 33% (20 of 60) of replicates by low copy number (LCN) HRM analysis, treatment with UDG decreased the mutation frequency to 8% (5 of 60), 17% (10 of 57) and 5% (3 of 57), respectively. UDG treatment resulted in a similar reduction in mutations identified by sequencing from 12 in 10 reactions to 7 in 32 reactions with all 7 remaining mutations consistent with deamination of 5-methylcytosine to thymine. Further, UDG treatment reduced the number of mutations identified in proto-oncogene B-Raf (BRAF) exon 15 (15/46 to 0/48) and epidermal growth factor receptor (EGFR) exon 19 (16/29 to 1/28). However, UDG treatment did not affect detection of true mutations in KRAS and EGFR.
Biospecimens
TissueLungPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
DNADNA sequencingDNASNP assayPre-analytical Factors
Classification Pre-Analytical Factor Value(s) SNP assay Specific Targeted nucleic acid AKT1BRAFEGFRSNP assay Specific Technology platform HRMSequencingSNP assay Specific Template modification 0.1 units UDG/reaction0.25 units UDG/reaction0.5 units UDG/reaction1.0 units UDG/reactionNo UDG addedSNP assay Specific Template/input amount 25 ng5 ng